“How I treat” a patient with DNMT3A-mutated AML in remission post intensive chemotherapy

https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/ac/db/b3/acdbb369-23a5-f4ef-1717-3b6405d74b6f/mza_5928252466954251512.jpeg/600x600bb.jpg

AML Hub

Scientific Education Support

29 episodes

1 week ago

The AML Hub is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education on acute myeloid leukemia (AML). Our aim is to enhance knowledge in AML through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.

Hosted on Acast. See acast.com/privacy for more information.

Education

RSS

All content for AML Hub is the property of Scientific Education Support and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Hosted on Acast. See acast.com/privacy for more information.

Education

https://assets.pippa.io/shows/undefined/1585645708468-f1820b05797bc1563ae18cf50ab2ecce.jpeg

“How I treat” a patient with DNMT3A-mutated AML in remission post intensive chemotherapy

AML Hub

5 minutes 59 seconds

1 year ago

“How I treat” a patient with DNMT3A-mutated AML in remission post intensive chemotherapy

The AML Hub was pleased to speak with Cristina Papayannidis, Universitaria di Bologna, Bologna, IT. We asked, How do you treat a patient with DNMT3A-mutated acute myeloid leukemia (AML) in remission post intensive chemotherapy?

This educational resource is independently supported by Bristol Myers Squibb. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.